First-in-Human Evaluation of Site-Specifically Labeled89Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer

Article Properties
  • Language
    English
  • DOI (url)
    10.2967/jnumed.123.266392
  • Publication Date
    2024/01/25
  • Journal
    Journal of Nuclear Medicine
  • Indian UGC (journal)
  • Refrences
    30
  • Randy Yeh
  • Joseph A. O’Donoghue
  • Vetri Sudar Jayaprakasam
  • Audrey Mauguen
  • Ryan Min
  • Sue Park
  • Julia P. Brockway
  • Jacqueline F. Bromberg
  • W Iris Zhi
  • Mark E. Robson
  • Rachel Sanford
  • Shanu Modi
  • Brian J. Agnew
  • Serge K. Lyashchenko
  • Jason S. Lewis
  • Gary A. Ulaner
  • Brian M. Zeglis
Cite
Yeh, Randy, et al. “First-in-Human Evaluation of Site-Specifically Labeled89Zr-Pertuzumab in Patients With HER2-Positive Breast Cancer”. Journal of Nuclear Medicine, vol. 65, no. 3, 2024, pp. 386-93, https://doi.org/10.2967/jnumed.123.266392.
Yeh, R., O’Donoghue, J. A., Jayaprakasam, V. S., Mauguen, A., Min, R., Park, S., Brockway, J. P., Bromberg, J. F., Zhi, W. I., Robson, M. E., Sanford, R., Modi, S., Agnew, B. J., Lyashchenko, S. K., Lewis, J. S., Ulaner, G. A., & Zeglis, B. M. (2024). First-in-Human Evaluation of Site-Specifically Labeled89Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer. Journal of Nuclear Medicine, 65(3), 386-393. https://doi.org/10.2967/jnumed.123.266392
Yeh R, O’Donoghue JA, Jayaprakasam VS, Mauguen A, Min R, Park S, et al. First-in-Human Evaluation of Site-Specifically Labeled89Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer. Journal of Nuclear Medicine. 2024;65(3):386-93.
Journal Categories
Medicine
Medicine (General)
Medicine
Medicine (General)
Medical physics
Medical radiology
Nuclear medicine
You May Also Like
Refrences
Title Journal Journal Categories Citations Publication Date
Pertuzumab Charge Variant Analysis and Complementarity-Determining Region Stability Assessment to Deamidation Analytical Chemistry
  • Science: Chemistry: Analytical chemistry
  • Science: Chemistry: Analytical chemistry
  • Science: Chemistry: Analytical chemistry
  • Science: Chemistry
 3 2023
DESTINY-changing results for advanced breast cancer New England Journal of Medicine
  • Medicine: Medicine (General)
  • Medicine: Internal medicine
  • Medicine: Medicine (General)
  • Medicine: Medicine (General)
 2022
Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT Radiology
  • Medicine: Medicine (General): Medical physics. Medical radiology. Nuclear medicine
  • Medicine: Medicine (General): Medical physics. Medical radiology. Nuclear medicine
  • Medicine: Medicine (General)
  • Medicine: Medicine (General)
 35 2020
Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort European Journal of Cancer
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Medicine (General)
 28 2020
The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and In vivo Performance of 89Zr-DFO-Pertuzumab Theranostics
  • Medicine: Medicine (General)
  • Medicine: Medicine (General)
 32 2020